SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-024017
Filing Date
2021-05-05
Accepted
2021-05-05 16:01:27
Documents
14
Period of Report
2021-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fate-8k_20210505.htm   iXBRL 8-K 39105
2 EX-99.1 fate-ex991_19.htm EX-99.1 235665
3 GRAPHIC g2a5hyyvsza0000001.jpg GRAPHIC 14966
  Complete submission text file 0001564590-21-024017.txt   445803

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fate-20210505.xsd EX-101.SCH 5808
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20210505_lab.xml EX-101.LAB 19473
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20210505_pre.xml EX-101.PRE 11658
7 EXTRACTED XBRL INSTANCE DOCUMENT fate-8k_20210505_htm.xml XML 3555
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 21893086
SIC: 2836 Biological Products, (No Diagnostic Substances)